Ibudilast

Drug Profile

Ibudilast

Alternative Names: AV-11; AV-411; Eyevinal; Ibinal; KC-404; Ketas; MN-166; Pinatos

Latest Information Update: 01 Jul 2017

Price : $50

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer Banyu; Kyorin Pharmaceutical; MediciNova; National Institute of Neurological Disorders and Stroke; National Institute on Drug Abuse; Senju Pharmaceutical; University of California at Los Angeles; University of Colorado at Boulder; University of New South Wales
  • Class 2 ring heterocyclic compounds; Anti-inflammatories; Antiasthmatics; Antihyperglycaemics; Antiplatelets; Non-opioid analgesics; Nootropics; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Astrocyte inhibitors; Cytokine modulators; Glial cell modulators; Leukotriene receptor antagonists; Macrophage migration inhibitory factor inhibitors; Nitric oxide synthase inhibitors; Phosphodiesterase 10A inhibitors; Toll-like receptor 4 antagonists; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Globoid cell leukodystrophy
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Asthma; Cerebrovascular disorders
  • Phase II Alcoholism; Amyotrophic lateral sclerosis; Multiple sclerosis; Opioid abuse
  • Phase I Drug abuse
  • Preclinical Brain injuries; Glioblastoma; Globoid cell leukodystrophy
  • Suspended Neuropathic pain
  • No development reported Headache
  • Discontinued Diabetic neuropathies; Diabetic retinopathy

Most Recent Events

  • 05 Jun 2017 Pharmacodynamics data from a preclinical study in Glioblastoma released by MediciNova
  • 22 Apr 2017 Updated efficacy and adverse events data from a phase Ib/IIa trial in Amyotrophic lateral sclerosis presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 27 Feb 2017 Preclinical trials in Glioblastoma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top